Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2024-05-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于对全资子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of guarantees provided by the company to its wholly-owned subsidiaries. It details the guarantee amounts, contractual terms, financial status of the subsidiaries, and approvals from the board and shareholders. There are no financial statements or comprehensive financial reports included, only information about guarantees and related approvals. The document is a regulatory announcement about financing guarantees, not a full financial report or earnings release. It fits best under Capital/Financing Update (CAP) as it concerns updates on company financing activities and guarantees.
2024-05-23 Chinese
安徽天禾律师事务所关于亿帆医药股份有限公司2023年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2023 Annual General Meeting (AGM) of Yifan Pharmaceutical Co., Ltd. It details the legality and compliance of the AGM's convening, attendance, voting procedures, and resolutions passed. The document does not contain financial statements or results but focuses on the legal aspects of the AGM process and its resolutions. It is not the AGM materials or presentations themselves, nor is it an announcement of voting results. Given the content and purpose, this document fits best under the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the meeting.
2024-05-17 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2023 Annual General Meeting (AGM) resolution announcement for Yifan Pharmaceutical Co., Ltd. It details the date, attendance, voting results on various proposals including the 2023 annual report, financial statements, profit distribution plan, and other corporate governance matters. It also includes legal opinions confirming the validity of the meeting and resolutions. The content is focused on the official announcement of the AGM resolutions and voting outcomes rather than the full AGM materials or presentations. The document length is 7737 characters, which is substantial but the content is clearly an announcement of voting results and resolutions passed at the AGM. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-05-17 Chinese
关于银杏叶丸获得新加坡注册批文的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about receiving a new product registration approval from the Singapore Health Sciences Authority. It details the product information, registration number, and potential impact on the company. The document is short (1044 characters) and serves as a regulatory announcement about a product approval, not a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product registration approval.
2024-05-13 Chinese
关于获得药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving an official approval notice from the National Medical Products Administration for a drug supplement application. It details the approval of a drug consistency evaluation and its potential impact on the company. The document is short (1011 characters) and serves as an announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed report data. It is not an earnings release, annual report, or any other financial filing. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant company event that does not fit other specific categories.
2024-04-24 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company about receiving a drug registration certificate from the national drug regulatory authority. It details the certificate information, product description, and potential impact on the company. The document is short (1102 characters) and is an announcement of a regulatory approval event, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not related to shareholder meetings, voting, or capital changes. It is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-04-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.